GlassScriptPhysician profile
Steven J Donnelly
NPI 1790710572
$5,892.70
in general payments reported to CMS, 2019-2025
26 companies · $883 in 2025
The $883 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $690 · 2020: $490 · 2021: $465 · 2022: $1,632 · 2023: $567 · 2024: $1,166 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,590 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,589.89 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,233.30 | 2019-2025 | Tryptyr, Rocklatan, Simbrinza |
| Abbvie INC. | $696.36 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Notal Vision, INC. | $576.42 | 2022 | |
| Novartis Pharmaceuticals Corporation | $352.37 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $352.35 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Rxsight INC | $329.10 | 2022-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Tarsus Pharmaceuticals, INC. | $301.54 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $249.30 | 2019-2024 | Cequa |
| Aerie Pharmaceuticals, INC. | $196.89 | 2019-2021 | |
| Sight Sciences, INC. | $193.83 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Shire North American Group INC | $185.81 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $176.80 | 2019-2021 | |
| Dompe US, INC. | $152.38 | 2022-2025 | Oxervate |
| Carl Zeiss Meditec USA, INC. | $130.84 | 2024 | Atlas 500, Quatera 700, Iolmaster 700 |
| Biotissue Holdings INC. | $123.13 | 2019-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $106.93 | 2020-2021 | |
| Eyevance Pharmaceuticals LLC | $97.38 | 2019-2022 | |
| Oyster Point Pharma, INC. | $93.73 | 2022-2024 | Tyrvaya |
| Glaukos Corporation | $86.35 | 2019-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Ocular Therapeutix, INC. | $59.72 | 2021-2024 | Dextenza |
| Kala Pharmaceuticals, INC. | $48.18 | 2019-2022 | |
| Harrow Eye, LLC | $45.80 | 2024-2025 | Vevye |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Rayner Intraocular Lenses Limited | $28.03 | 2023 | Rayone Aspheric, Rayone Emv, Omidria |
| Amgen INC. | $19.41 | 2025 | Tepezza |
| Omeros Corporation | $17.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Donnelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.